Discussion on “Predictively consistent prior effective sample sizes,” by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'Hagan

Atanu Biswas and Jean‐François Angers

Biometrics, 2020, vol. 76, issue 2, 591-594

Abstract: We extend the approach of finding effective sample size for a typical phase II clinical trial having efficacy and toxicity as two components of the response vector. The case of binary efficacy and binary toxicity is illustrated under Dirichlet and multivariate T priors.

Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1111/biom.13247

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bla:biomet:v:76:y:2020:i:2:p:591-594

Ordering information: This journal article can be ordered from
http://www.blackwell ... bs.asp?ref=0006-341X

Access Statistics for this article

More articles in Biometrics from The International Biometric Society
Bibliographic data for series maintained by Wiley Content Delivery ().